<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ANG</journal-id>
<journal-id journal-id-type="hwp">spang</journal-id>
<journal-id journal-id-type="nlm-ta">Angiology</journal-id>
<journal-title>Angiology</journal-title>
<issn pub-type="ppub">0003-3197</issn>
<issn pub-type="epub">1940-1574</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0003319712438956</article-id>
<article-id pub-id-type="publisher-id">10.1177_0003319712438956</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Cardiac Arrhythmias</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Serum γ-Glutamyltransferase Activity in Patients With Nonvalvular Atrial Fibrillation</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Tekin</surname>
<given-names>Gulacan</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319712438956">1</xref>
<xref ref-type="corresp" rid="corresp1-0003319712438956"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tekin</surname>
<given-names>Yusuf Kenan</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-0003319712438956">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Senarslan</surname>
<given-names>Dılsad Amanvermez</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff3-0003319712438956">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gocmen</surname>
<given-names>Ayse Yesım</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff4-0003319712438956">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Senarslan</surname>
<given-names>Omer</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff5-0003319712438956">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Erbay</surname>
<given-names>Alı Rıza</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319712438956">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0003319712438956"><label>1</label>Department of Cardiology, Faculty of Medicine, Bozok University, Yozgat, Turkey</aff>
<aff id="aff2-0003319712438956"><label>2</label>Emergency Department, Government Hospital, Yozgat, Turkey</aff>
<aff id="aff3-0003319712438956"><label>3</label>Department of Cardiovascular Surgery, Faculty of Medicine, Bozok University, Yozgat, Turkey</aff>
<aff id="aff4-0003319712438956"><label>4</label>Department of Biochemistry, Faculty of Medicine, Bozok University, Yozgat, Turkey</aff>
<aff id="aff5-0003319712438956"><label>5</label>Department of Cardiology, Government Hospital, Yozgat, Turkey</aff>
<author-notes>
<corresp id="corresp1-0003319712438956">Gulacan Tekin, Department of Cardiology, Faculty of Medicine, Bozok University, Yozgat 66100, Turkey Email: <email>gulacantekin@hotmail.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2013</year>
</pub-date>
<volume>64</volume>
<issue>2</issue>
<fpage>157</fpage>
<lpage>160</lpage>
<permissions>
<copyright-statement>© The Author(s) 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Procoagulant and prothrombotic states in patients with chronic atrial fibrillation (AF) are higher than those in patients with normal sinus rhythm. We assessed and compared serum γ-glutamyltranferase (GGT) activity in elderly patients with nonvalvular AF and control participants with normal sinus rhythm. Consecutive patients (n = 81) with nonvalvular chronic AF and 210 age- and gender-matched control participants with normal sinus rhythm were retrospectively included in the study from the outpatient cardiology clinic. Presence of coronary artery disease, hypertension, gender, hyperlipidemia, diabetes mellitus, smoking status, glucose, total cholesterol, triglycerides, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and ejection fraction were comparable between the 2 groups (<italic>P</italic> &gt; .05 for all). However, serum γ-GGT activity was significantly higher (<italic>P</italic> = .003) in patients with AF compared with those without AF. We have shown that serum γ-GGT activity is independently associated with chronic nonvalvular AF. </p>
</abstract>
<kwd-group>
<kwd>atrial fibrillation</kwd>
<kwd>γ-glutamyltransferase</kwd>
<kwd>inflammation</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0003319712438956">
<title>Introduction</title>
<p>Atrial fibrillation (AF) is one of the most common clinical arrhythmia.<sup>
<xref ref-type="bibr" rid="bibr1-0003319712438956">1</xref><xref ref-type="bibr" rid="bibr2-0003319712438956"/>–<xref ref-type="bibr" rid="bibr3-0003319712438956">3</xref>
</sup> Its prevalence increases with age, from about 2% in the general population to 5% in people older than 65 years and 10% in people older than 75 years,<sup>
<xref ref-type="bibr" rid="bibr4-0003319712438956">4</xref>,<xref ref-type="bibr" rid="bibr5-0003319712438956">5</xref>
</sup> and it contributes to an increased risk of stroke, heart failure, and mortality.<sup>
<xref ref-type="bibr" rid="bibr2-0003319712438956">2</xref>
</sup> The fundamental mechanisms underlying AF remain poorly understood. Recent studies have shown that there is a link between oxidative stress, systemic inflammation, and AF.<sup>
<xref ref-type="bibr" rid="bibr6-0003319712438956">6</xref><xref ref-type="bibr" rid="bibr7-0003319712438956"/>–<xref ref-type="bibr" rid="bibr8-0003319712438956">8</xref>
</sup> High-sensitivity C-reactive protein (CRP), which is a systemic inflammation marker, is associated with increased risk of early AF recurrence.<sup>
<xref ref-type="bibr" rid="bibr9-0003319712438956">9</xref><xref ref-type="bibr" rid="bibr10-0003319712438956"/>–<xref ref-type="bibr" rid="bibr11-0003319712438956">11</xref>
</sup> It is thought that platelet activity increased in chronic and paroxysmal AF.<sup>
<xref ref-type="bibr" rid="bibr12-0003319712438956">12</xref>
<xref ref-type="bibr" rid="bibr13-0003319712438956"/>–<xref ref-type="bibr" rid="bibr14-0003319712438956">14</xref>
</sup>
</p>
<p>Serum γ-glutamyltransferase (GGT) activity is a frequently used test that is inexpensive, easily accessible, highly sensitive marker of hepatobiliary dysfunction, and alcohol consumption.<sup>
<xref ref-type="bibr" rid="bibr15-0003319712438956">15</xref>
</sup> According to the Framingham Heart Study including 3451 participants, elevated serum GGT activity is associated with increased onset of metabolic syndrome and predicts cardiovascular disease.<sup>
<xref ref-type="bibr" rid="bibr16-0003319712438956">16</xref>
</sup> An epidemiological investigation including 163 944 participants showed that GGT activity was independently associated with cardiovascular mortality.<sup>
<xref ref-type="bibr" rid="bibr17-0003319712438956">17</xref>
</sup> Recent studies showed that increased serum GGT activity is associated with increased oxidative stress and activation of systemic inflammation in humans.<sup>
<xref ref-type="bibr" rid="bibr11-0003319712438956">11</xref>,<xref ref-type="bibr" rid="bibr18-0003319712438956">18</xref>,<xref ref-type="bibr" rid="bibr19-0003319712438956">19</xref></sup> Therefore, both AF and GGT activities are associated with systemic inflammation and oxidative stress. Also, there is an association between GGT activity and platelet hyperactivity. It is thought that human platelets contain isoenzyme GGT4 and continuous disruption of platelets can influence GGT activity.<sup>
<xref ref-type="bibr" rid="bibr20-0003319712438956">20</xref>,<xref ref-type="bibr" rid="bibr21-0003319712438956">21</xref>
</sup> </p>
<p>We aimed to assess the clinical, echocardiographic, hematological, and biochemical parameters in patients with nonvalvular chronic AF and control participants, focusing on serum GGT activity in elderly patients, independently of liver disease and alcohol consumption.</p>
</sec>
<sec id="section2-0003319712438956" sec-type="methods">
<title>Patients and Methods</title>
<p>Consecutive patients (n = 81) with nonvalvular chronic AF and 210 age- and gender-matched control participants with normal sinus rhythm were retrospectively included in the study from the outpatient cardiology clinic between June 2009 and March 2010. In total, 156 patients with AF were screened and 44 patients were excluded due to exclusion criteria as explained in the next paragraph. The following clinical and demographic parameters were recorded: age, sex, hypertension (known hypertension treated with antihypertensive drugs and 2 or more blood pressure recordings greater than 140/90 mm Hg), diabetes mellitus (known diabetes treated with diet or drugs or both; or either a fasting serum glucose &gt;126 mg/dL), and hypercholesterolemia (known treated hypercholesterolemia or fasting or nonfasting serum cholesterol concentrations &gt;200 mg/dL). Current cigarette smoking was defined as active smoking within the past 12 months. Coronary artery disease was defined as &gt;50% luminal narrowing of epicardial coronary arteries, and normal coronary arteries were defined as the absence of significant coronary stenosis (&lt;50%) in any epicardial coronary arteries in whom coronary angiography was previously performed. All patients and control individuals had echocardiographic examination to rule out valvular heart disease.</p>
<p>Patients with acute coronary syndromes, recent myocardial infarction (&lt;4 weeks), heart failure, right heart failure, recent stroke history (&lt;4 weeks), infections within past 4 weeks, hematological diseases such as polycythemia vera, thrombophilia, reported alcohol consumption, hepatobiliary disease, chronic or acute hepatitis, chronic renal failure, connective tissue inflammatory disease or active malignancies, and acute AF were not included in the study. Chronic AF, defined as lasting 1 week or more, was included in the study. Patients with AF and concomitant valvular heart disease were excluded.</p>
<p>Hematological markers, GGT activity, glucose, total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides levels were measured using an Architect Cİ16200 (Abbott, Germany) analyzer in all patients and control participants.</p>
<sec id="section3-0003319712438956">
<title>Statistical Analysis</title>
<p>Results are expressed as the mean ± standard deviation and percentage. The differences between 2 groups were tested for significance by chi-square and independent samples <italic>t</italic> tests. Differences between 2 groups were considered significant at <italic>P</italic> value &lt;.05 (2-tailed). We investigated the association of different variables with AF using logistic regression analysis. Parameters namely, age, presence of hypertension, diabetes mellitus, GGT activity, and ejection fraction were included in regression analysis. Statistical analyses were performed using SPSS 15.0 Statistical Package Program for Windows (SPSS Inc, Chicago, Illinois).</p>
</sec>
</sec>
<sec id="section4-0003319712438956">
<title>Results</title>
<p>The mean age of patients with and without chronic AF was 73 ± 8 and 74 ± 6 years, respectively (<italic>P</italic> = .88). Baseline characteristics of patients and control individuals are presented in <xref ref-type="table" rid="table1-0003319712438956">Table 1</xref>. Presence of coronary artery disease, hypertension, gender, hyperlipidemia, diabetes mellitus, smoking status was comparable between the 2 groups (<italic>P</italic> &gt; .05 for all). However, serum GGT activity was significantly higher in patients with AF compared with those without AF (<xref ref-type="table" rid="table1-0003319712438956">Table 1</xref>). Logistic regression analysis revealed that serum GGT activity was significantly and independently associated with AF (<xref ref-type="table" rid="table2-0003319712438956">Table 2</xref>).</p>
<table-wrap id="table1-0003319712438956" position="float">
<label>Table 1.</label>
<caption>
<p>Comparison of Patient With Atrial Fibrillation and Control Individuals</p>
</caption>
<graphic alternate-form-of="table1-0003319712438956" xlink:href="10.1177_0003319712438956-table1.tif"/>
<table>
<thead>
<tr>
<th>Variables</th>
<th>Atrial Fibrillation, n = 81</th>
<th>Control Individuals, n = 210</th>
<th>
<italic>P</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>73 ± 8</td>
<td>74 ± 6</td>
<td>.88</td>
</tr>
<tr>
<td>Gender (female) (%)</td>
<td>52 (64%)</td>
<td>113 (54%)</td>
<td>.11</td>
</tr>
<tr>
<td>Coronary artery disease, %</td>
<td>13 (24%)</td>
<td>41 (29%)</td>
<td>.61</td>
</tr>
<tr>
<td>Hypertension, %</td>
<td>60 (74%)</td>
<td>136 (65%)</td>
<td>.16</td>
</tr>
<tr>
<td>Diabetes mellitus, %</td>
<td>12 (15%)</td>
<td>33 (16%)</td>
<td>1.00</td>
</tr>
<tr>
<td>Hyperlipidemia, %</td>
<td>18 (22%)</td>
<td>59 (28%)</td>
<td>.37</td>
</tr>
<tr>
<td>Smoking, %</td>
<td>14 (17%)</td>
<td>55 (26%)</td>
<td>.12</td>
</tr>
<tr>
<td>White blood cells (×10<sup>3</sup>/µL)</td>
<td>7.4 ± 2.2</td>
<td>7.1 ± 1.8</td>
<td>.36</td>
</tr>
<tr>
<td>Glucose, mg/dL</td>
<td>113 ± 37</td>
<td>109 ± 40</td>
<td>.53</td>
</tr>
<tr>
<td>Total cholesterol, mg/dL</td>
<td>172 ± 45</td>
<td>180 ± 36</td>
<td>.10</td>
</tr>
<tr>
<td>Triglycerides, mg/dL</td>
<td>117 ± 69</td>
<td>129 ± 67</td>
<td>.19</td>
</tr>
<tr>
<td>LDL cholesterol, mg/dL</td>
<td>108 ± 32</td>
<td>114 ± 28</td>
<td>.14</td>
</tr>
<tr>
<td>HDL cholesterol, mg/dL</td>
<td>37 ± 9</td>
<td>37 ± 10</td>
<td>.88</td>
</tr>
<tr>
<td>GGT activity, IU/L</td>
<td>27 ± 18</td>
<td>20 ± 13</td>
<td>.003</td>
</tr>
<tr>
<td>Ejection fraction, %</td>
<td>61 ± 4</td>
<td>62 ± 4</td>
<td>.13</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0003319712438956">
<p>Abbreviations: LDL, low-density lipoprotein; HDL, high-density lipoprotein; GGT, γ-glutamyltransferase.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table2-0003319712438956" position="float">
<label>Table 2.</label>
<caption>
<p>Logistic Regression Analysis</p>
</caption>
<graphic alternate-form-of="table2-0003319712438956" xlink:href="10.1177_0003319712438956-table2.tif"/>
<table>
<thead>
<tr>
<th>Variables</th>
<th>Odds Ratio</th>
<th>Confidence Interval</th>
<th>
<italic>P</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>−0.004</td>
<td>(−0.008-0.007)</td>
<td>.94</td>
</tr>
<tr>
<td>Hypertension</td>
<td>0.94</td>
<td>(−0.02-0.20)</td>
<td>.11</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>0.06</td>
<td>(−0.22-0.06)</td>
<td>.29</td>
</tr>
<tr>
<td>Ejection fraction</td>
<td>0.05</td>
<td>(−0.18-0.007)</td>
<td>.37</td>
</tr>
<tr>
<td>GGT activity (IU/L)</td>
<td>0.19</td>
<td>(0.002-0.009)</td>
<td>.001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0003319712438956">
<p>Abbreviation: GGT, γ-glutamyltranferase.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section5-0003319712438956">
<title>Discussion</title>
<p>Our main finding is that patients with nonvalvular chronic AF have higher serum GGT activity compared with those with normal sinus rhythm. Additionally, AF is independently and positively associated with serum GGT activity. Paroxysmal and chronic AF are associated with platelet hyperactivity.<sup>
<xref ref-type="bibr" rid="bibr12-0003319712438956">12</xref>
<xref ref-type="bibr" rid="bibr13-0003319712438956"/>–<xref ref-type="bibr" rid="bibr14-0003319712438956">14</xref>
</sup> It is considered that human platelets contain GGT4 isoenzyme. So that increased platelet activity and sustained platelet disruption may result in an increase in serum GGT activity.<sup>
<xref ref-type="bibr" rid="bibr20-0003319712438956">20</xref>,<xref ref-type="bibr" rid="bibr21-0003319712438956">21</xref>
</sup> Also development of AF is associated with inflammatory processes and CRP (an inflammatory marker) is elevated in chronic AF<sup>
<xref ref-type="bibr" rid="bibr22-0003319712438956">22</xref>
</sup> and elevated serum GGT activity associated with increased CRP.<sup>
<xref ref-type="bibr" rid="bibr16-0003319712438956">16</xref>
</sup>
</p>
<p>Chronic AF is a frequent arrhythmia that can cause thromboembolic events and stroke. The procoagulant and prothrombotic states in patients with chronic AF are higher than those in patients with normal sinus rhythm.<sup>
<xref ref-type="bibr" rid="bibr12-0003319712438956">12</xref>
</sup>
<sup>-</sup>
<sup>
<xref ref-type="bibr" rid="bibr14-0003319712438956">14</xref>
</sup>
<sup>,</sup>
<sup>
<xref ref-type="bibr" rid="bibr23-0003319712438956">23</xref>
</sup>
<sup>,</sup>
<sup>
<xref ref-type="bibr" rid="bibr24-0003319712438956">24</xref>
</sup> The AF is associated with a prothrombotic state related to endothelial dysfunction.<sup>
<xref ref-type="bibr" rid="bibr25-0003319712438956">25</xref>
</sup> Oxidative stress is associated with AF<sup><xref ref-type="bibr" rid="bibr26-0003319712438956">26</xref></sup> and in some studies antioxidants; ascorbate<sup><xref ref-type="bibr" rid="bibr27-0003319712438956">27</xref></sup> and N-acetylcysteine<sup><xref ref-type="bibr" rid="bibr28-0003319712438956">28</xref></sup> are reported to decrease postoperative AF in patients undergoing cardiac surgery. Recent studies demonstrated a relationship between inflammation and AF.<sup>
<xref ref-type="bibr" rid="bibr3-0003319712438956">3</xref>
</sup>
<sup>,</sup>
<sup>
<xref ref-type="bibr" rid="bibr22-0003319712438956">22</xref>
</sup> Inflammatory markers (eg, CRP) are elevated in paroxysmal and persistent AF.<sup>
<xref ref-type="bibr" rid="bibr1-0003319712438956">1</xref>
</sup> In longer duration AF, CRP levels are higher than that of shorter duration AF, suggesting a close association between AF and systemic inflammation.<sup>
<xref ref-type="bibr" rid="bibr1-0003319712438956">1</xref>
</sup>
<sup>,</sup>
<sup>
<xref ref-type="bibr" rid="bibr7-0003319712438956">7</xref>
</sup>
<sup>,</sup>
<sup>
<xref ref-type="bibr" rid="bibr8-0003319712438956">8</xref>
</sup> A prospective study (5806 participants aged 65 and older) reported that increased baseline CRP level predicts an increased incidence of AF.<sup><xref ref-type="bibr" rid="bibr29-0003319712438956">29</xref></sup> After bypass surgery, the baseline CRP levels are associated with increased postoperative development of AF.<sup>
<xref ref-type="bibr" rid="bibr30-0003319712438956">30</xref>
</sup>
</p>
<p>Serum GGT activity is a known marker of alcohol consumption and hepatic dysfunction and measurement of serum GGT activity is reliable, easy, and not expensive.<sup>
<xref ref-type="bibr" rid="bibr31-0003319712438956">31</xref>
</sup> The GGT is found in all cell membranes except erythrocytes, is involved in extracellular glutathione catabolism, and provides intracellular glutathione resynthesis and so reduces oxidant stress.<sup>
<xref ref-type="bibr" rid="bibr15-0003319712438956">15</xref>
</sup>
<sup>,<xref ref-type="bibr" rid="bibr16-0003319712438956">16</xref>
</sup> </p>
<p>In the general population, there might be an association between serum GGT activity and cardiovascular disease, and GGT activity might be a predictor of metabolic syndrome.<sup>
<xref ref-type="bibr" rid="bibr16-0003319712438956">16</xref>
</sup>
<sup>,<xref ref-type="bibr" rid="bibr18-0003319712438956">18</xref>,<xref ref-type="bibr" rid="bibr32-0003319712438956">32</xref>,<xref ref-type="bibr" rid="bibr33-0003319712438956">33</xref>
</sup> Elevated serum GGT activity associated with the activation of systemic inflammation and increased oxidative stress independently from metabolic syndrome,<sup>
<xref ref-type="bibr" rid="bibr18-0003319712438956">18</xref>
</sup>
<sup>,<xref ref-type="bibr" rid="bibr34-0003319712438956">34</xref>
</sup> suggesting that serum GGT is a marker of oxidative stress.<sup>
<xref ref-type="bibr" rid="bibr34-0003319712438956">34</xref><xref ref-type="bibr" rid="bibr35-0003319712438956"/><xref ref-type="bibr" rid="bibr36-0003319712438956"/><xref ref-type="bibr" rid="bibr37-0003319712438956"/>–<xref ref-type="bibr" rid="bibr38-0003319712438956">38</xref>
</sup> High activity of GGT might increase atherogenesis by binding to LDL and providing LDL oxidation.<sup>
<xref ref-type="bibr" rid="bibr39-0003319712438956">39</xref>
</sup> Studies also show that serum GGT activity was associated with CRP and F2-isoprostanes (a marker of oxidative damage).<sup>
<xref ref-type="bibr" rid="bibr34-0003319712438956">34</xref>
</sup>
</p>
<p>Our study is retrospective and we did not follow our patients prospectively. Our study only includes a small number of patients.</p>
<p>In conclusion, we have shown that serum GGT activity is independently associated with chronic AF. Further studies are needed to improve the clinical utility of GGT activity and to better understand the role of inflammation in the pathogenesis of AF. Randomized controlled prospective studies are needed to evaluate the relationship between chronic AF and serum GGT activity.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-0003319712438956">
<label>Declaration of Conflicting Interests</label>
<p>The authors declared no conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0003319712438956">
<label>Funding</label>
<p>The authors received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0003319712438956">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ozaydin</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Atrial fibrillation and inflammation</article-title>. <source>World J Cardiol</source>. <year>2010</year>;<volume>2</volume>(<issue>8</issue>):<fpage>243</fpage>–<lpage>250</lpage>.</citation>
</ref>
<ref id="bibr2-0003319712438956">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Issac</surname>
<given-names>TT</given-names>
</name>
<name>
<surname>Dokainish</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lakkis</surname>
<given-names>NM</given-names>
</name>
</person-group>. <article-title>Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data</article-title>. <source>J Am Coll Cardiol</source>. <year>2007</year>;<volume>50</volume>(<year>21</year>):<fpage>2021</fpage>–<lpage>2028</lpage>.</citation>
</ref>
<ref id="bibr3-0003319712438956">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Conen</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Osswald</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Albert</surname>
<given-names>C.M</given-names>
</name>
</person-group>. <article-title>Epidemiology of atrial fibrillation</article-title>. <source>Swiss Med Wkly</source>. <year>2009</year>;<volume>139</volume>(<issue>25-26</issue>):<fpage>346</fpage>–<lpage>352</lpage>.</citation>
</ref>
<ref id="bibr4-0003319712438956">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lake</surname>
<given-names>FR</given-names>
</name>
<name>
<surname>Cullen</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>de Klerk</surname>
<given-names>NH</given-names>
</name>
<name>
<surname>McCall</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Rosman</surname>
<given-names>DL</given-names>
</name>
</person-group>. <article-title>Atrial fibrillation and mortality in an elderly population</article-title>. <source>Aust N Z J Med</source>. <year>1989</year>;<volume>19</volume>(<issue>4</issue>):<fpage>321</fpage>–<lpage>326</lpage>.</citation>
</ref>
<ref id="bibr5-0003319712438956">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wolf</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Abbott</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Kannel</surname>
<given-names>WB</given-names>
</name>
</person-group>. <article-title>Atrial fibrillation as an independent risk factor for stroke: the Framingham Study</article-title>. <source>Stroke</source>. <year>1991</year>;<volume>22</volume>(<issue>8</issue>):<fpage>983</fpage>–<lpage>988</lpage>.</citation>
</ref>
<ref id="bibr6-0003319712438956">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Wagoner</surname>
<given-names>DR</given-names>
</name>
</person-group>. <article-title>Oxidative stress and inflammation in atrial fibrillation: role in pathogenesis and potential as a therapeutic target</article-title>. <source>J Cardiovasc Pharmacol</source>. <year>2008</year>;<volume>52</volume>(<issue>4</issue>):<fpage>306</fpage>–<lpage>313</lpage>.</citation>
</ref>
<ref id="bibr7-0003319712438956">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chung</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>DO</given-names>
</name>
<name>
<surname>Sprecher</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation</article-title>. <source>Circulation</source>. <year>2001</year>;<volume>104</volume>(<issue>24</issue>):<fpage>2886</fpage>–<lpage>2891</lpage>.</citation>
</ref>
<ref id="bibr8-0003319712438956">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Watanabe</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Takeishi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hirono</surname>
<given-names>O</given-names>
</name>
<etal/>
</person-group>. <article-title>C-reactive protein elevation predicts the occurrence of atrial structural remodeling in patients with paroxysmal atrial fibrillation</article-title>. <source>Heart Vessels</source>. <year>2005</year>;<volume>20</volume>(<issue>2</issue>):<fpage>45</fpage>–<lpage>49</lpage>.</citation>
</ref>
<ref id="bibr9-0003319712438956">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Conway</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Buggins</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hughes</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lip</surname>
<given-names>GY</given-names>
</name>
</person-group>. <article-title>Predictive value of indexes of inflammation and hypercoagulability on success of cardioversion of persistent atrial fibrillation</article-title>. <source>Am J Cardiol</source>. <year>2004</year>;<volume>94</volume>(<issue>4</issue>):<fpage>508</fpage>–<lpage>510</lpage>.</citation>
</ref>
<ref id="bibr10-0003319712438956">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Korantzopoulos</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kolettis</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Kountouris</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Oral vitamin C administration reduces early recurrence rates after electrical cardioversion of persistent atrial fibrillation and attenuates associated inflammation</article-title>. <source>Int J Cardiol</source>. <year>2005</year>;<volume>102</volume>(<issue>2</issue>):<fpage>321</fpage>–<lpage>326</lpage>.</citation>
</ref>
<ref id="bibr11-0003319712438956">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dernellis</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Panaretou</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation</article-title>. <source>Eur Heart J</source>. <year>2004</year>;<volume>25</volume>(<issue>13</issue>):<fpage>1100</fpage>–<lpage>1107</lpage>.</citation>
</ref>
<ref id="bibr12-0003319712438956">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Atalar</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Haznedaroglu</surname>
<given-names>IC</given-names>
</name>
<name>
<surname>Acil</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Patients with paroxysmal atrial fibrillation but not paroxysmal supraventricular tachycardia display evidence of platelet activation during arrhythmia</article-title>. <source>Platelets</source>. <year>2003</year>;<volume>14</volume>(<issue>7-8</issue>):<fpage>407</fpage>–<lpage>411</lpage>.</citation>
</ref>
<ref id="bibr13-0003319712438956">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sohara</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Amitani</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kurose</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Miyahara</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Atrial fibrillation activates platelets and coagulation in a time-dependent manner: a study in patients with paroxysmal atrial fibrillation</article-title>. <source>J Am Coll Cardiol</source>. <year>1997</year>;<volume>29</volume>(<issue>1</issue>):<fpage>106</fpage>–<lpage>112</lpage>.</citation>
</ref>
<ref id="bibr14-0003319712438956">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Colkesen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Acil</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Abayli</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>Mean platelet volume is elevated during paroxysmal atrial fibrillation: a marker of increased platelet activation?</article-title> <source>Blood Coagul Fibrinolysis</source>. <year>2008</year>;<volume>19</volume>(<issue>5</issue>):<fpage>411</fpage>–<lpage>414</lpage>.</citation>
</ref>
<ref id="bibr15-0003319712438956">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Whitfield</surname>
<given-names>JB</given-names>
</name>
</person-group>. <article-title>Gamma-glutamyl transferase</article-title>. <source>Crit Rev Clin Lab Sci</source>. <year>2001</year>;<volume>38</volume>(<issue>4</issue>):<fpage>263</fpage>–<lpage>355</lpage>.</citation>
</ref>
<ref id="bibr16-0003319712438956">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Robins</surname>
<given-names>SJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2007</year>;<volume>27</volume>(<issue>1</issue>):<fpage>127</fpage>–<lpage>133</lpage>.</citation>
</ref>
<ref id="bibr17-0003319712438956">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruttmann</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Brant</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Concin</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults</article-title>. <source>Circulation</source>. <year>2005</year>;<volume>112</volume>(<issue>14</issue>):<fpage>2130</fpage>–<lpage>2137</lpage>.</citation>
</ref>
<ref id="bibr18-0003319712438956">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Ha</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>JH</given-names>
</name>
<etal/>
</person-group>. <article-title>Gamma-glutamyltransferase and diabetes: a 4 year follow-up study</article-title>. <source>Diabetologia</source>. <year>2003</year>;<volume>46</volume>(<issue>3</issue>):<fpage>359</fpage>–<lpage>364</lpage>.</citation>
</ref>
<ref id="bibr19-0003319712438956">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamada</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tomiyama</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yambe</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Elevated serum levels of alanine aminotransferase and gamma glutamyltransferase are markers of inflammation and oxidative stress independent of the metabolic syndrome</article-title>. <source>Atherosclerosis</source>. <year>2006</year>;<volume>189</volume>(<issue>1</issue>):<fpage>198</fpage>–<lpage>205</lpage>.</citation>
</ref>
<ref id="bibr20-0003319712438956">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gürdöl</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Nwose</surname>
<given-names>OM</given-names>
</name>
<name>
<surname>Mikhailidis</surname>
<given-names>DP</given-names>
</name>
</person-group>. <article-title>Gamma-glutamyl transferase activity in human platelets: quantification of activity, isoenzyme characterization and potential clinical relevance</article-title>. <source>Platelets</source>. <year>1995</year>;<volume>6</volume>(<issue>4</issue>):<fpage>200</fpage>–<lpage>203</lpage>.</citation>
</ref>
<ref id="bibr21-0003319712438956">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bolodeoku</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Ganotakis</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Mikhailidis</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Winder</surname>
<given-names>AF</given-names>
</name>
</person-group>. <article-title>Correlation between serum gamma-glutamyl transferase activity and the platelet count</article-title>. <source>Platelets</source>. <year>1997</year>;<volume>8</volume>(<issue>5</issue>):<fpage>333</fpage>–<lpage>335</lpage>.</citation>
</ref>
<ref id="bibr22-0003319712438956">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Engelmann</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Svendsen</surname>
<given-names>JH</given-names>
</name>
</person-group>. <article-title>Inflammation in the genesis and perpetuation of atrial fibrillation</article-title>. <source>Eur Heart J</source>. <year>2005</year>;<volume>26</volume>(<issue>20</issue>):<fpage>2083</fpage>–<lpage>2092</lpage>.</citation>
</ref>
<ref id="bibr23-0003319712438956">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feng</surname>
<given-names>D</given-names>
</name>
<name>
<surname>D’Agostino</surname>
<given-names>BR</given-names>
</name>
<name>
<surname>Silberschatz</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Hemostatic state and atrial fibrillation (The Framingham Offspring Study)</article-title>. <source>Am J Cardiol</source>. <year>2001</year>;<volume>87</volume>(<issue>2</issue>):<fpage>168</fpage>–<lpage>171</lpage>.</citation>
</ref>
<ref id="bibr24-0003319712438956">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamaguchi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Furui</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Taniguchi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sotobata</surname>
<given-names>I</given-names>
</name>
</person-group>. <article-title>Plasma b-thromboglobulin and platelet factor 4 concentrations in patients with atrial fibrillation</article-title>. <source>Jpn Heart J</source>. <year>1986</year>;<volume>27</volume>(<issue>4</issue>):<fpage>481</fpage>–<lpage>487</lpage>. </citation>
</ref>
<ref id="bibr25-0003319712438956">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kastin</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>W</given-names>
</name>
</person-group>. <article-title>Gamma glutamyl transpeptidase is a dynamic indicator of endothelial response to stroke</article-title>. <source>Exp Neurol</source>. <year>2007</year>;<volume>203</volume>(<issue>1</issue>):<fpage>116</fpage>–<lpage>122</lpage>.</citation>
</ref>
<ref id="bibr26-0003319712438956">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neuman</surname>
<given-names>RB</given-names>
</name>
<name>
<surname>Bloom</surname>
<given-names>HL</given-names>
</name>
<name>
<surname>Shukrullah</surname>
<given-names>I</given-names>
</name>
<etal/>
</person-group>. <article-title>Oxidative stress markers are associated with persistent atrial fibrillation</article-title>. <source>Clin Chem</source>. <year>2007</year>;<volume>53</volume>(<issue>9</issue>):<fpage>1652</fpage>–<lpage>1657</lpage>.</citation>
</ref>
<ref id="bibr27-0003319712438956">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carnes</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Nakayama</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodelling and decreases the incidence of postoperative atrial fibrillation</article-title>. <source>Circ Res</source>. <year>2001</year>;<volume>89</volume>(<issue>6</issue>):<fpage>E32</fpage>–<lpage>E38</lpage>.</citation>
</ref>
<ref id="bibr28-0003319712438956">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ozaydin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Peker</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Erdogan</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>N-acetylcysteine for the prevention of postoperative atrial fibrillation: a prospective, randomized, placebo controlled pilot study</article-title>. <source>Eur Heart J</source>. 2008;29(5):625-631.</citation>
</ref>
<ref id="bibr29-0003319712438956">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aviles</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>DO</given-names>
</name>
<name>
<surname>Apperson-Hansen</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Inflammation as a risk factor for atrial fibrillation</article-title>. <source>Circulation</source>. <year>2003</year>;<volume>108</volume>(<issue>24</issue>):<fpage>3006</fpage>–<lpage>3010</lpage>.</citation>
</ref>
<ref id="bibr30-0003319712438956">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lo</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Fijnheer</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Nierich</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Bruins</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kalkman</surname>
<given-names>CJ</given-names>
</name>
</person-group>. <article-title>C-reactive protein is a risk indicator for atrial fibrillation after myocardial revascularization</article-title>. <source>Ann Thorac Surg</source>. <year>2005</year>;<volume>79</volume>(<issue>5</issue>):<fpage>1530</fpage>–<lpage>1535</lpage>.</citation>
</ref>
<ref id="bibr31-0003319712438956">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rhone</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>White</surname>
<given-names>FM</given-names>
</name>
</person-group>. <article-title>Effects of storage in the cold on activity of gamma-glutamyltransferase in serum</article-title>. <source>Clin Chem</source>. <year>1976</year>;<volume>22</volume>(<issue>1</issue>):<fpage>103</fpage>–<lpage>104</lpage>.</citation>
</ref>
<ref id="bibr32-0003319712438956">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nilssen</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Forde</surname>
<given-names>O.H</given-names>
</name>
<name>
<surname>Brenn</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>The Tromso Study: distribution and population determinants of gamma-glutamyltransferase</article-title>. <source>Am J Epidemiol</source>. <year>1990</year>;<volume>132</volume>(<issue>2</issue>):<fpage>318</fpage>–<lpage>326</lpage>.</citation>
</ref>
<ref id="bibr33-0003319712438956">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Jacobs</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Gross</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Gamma glutamyltransferase is a predictor of incident diabetes and hypertension: the CARDIA study</article-title>. <source>Clin Chem</source>. <year>2003</year>;<volume>49</volume>(<issue>8</issue>):<fpage>1358</fpage>–<lpage>1366</lpage>.</citation>
</ref>
<ref id="bibr34-0003319712438956">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lim</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Chun</surname>
<given-names>BY</given-names>
</name>
<name>
<surname>Kam</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jacobs</surname>
<given-names>DR</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Lee</surname>
<given-names>DH</given-names>
</name>
</person-group>. <article-title>Is serum gamma glutamyltransferase inversely associated with serum antioxidants as a marker of oxidative stress?</article-title> <source>Free Radic Biol Med</source>. <year>2004</year>;<volume>37</volume>(<issue>7</issue>):<fpage>1018</fpage>–<lpage>1023</lpage>.</citation>
</ref>
<ref id="bibr35-0003319712438956">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paolicchi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Minotti</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Tonarelli</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Gamma-glutamyl transpeptidase-dependent iron reduction and LDL oxidation—a potential mechanism in atherosclerosis</article-title>. <source>J Investig Med</source>. <year>1999</year>;<volume>47</volume>(<issue>3</issue>):<fpage>151</fpage>–<lpage>160</lpage>.</citation>
</ref>
<ref id="bibr36-0003319712438956">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abramson</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Hooper</surname>
<given-names>WC</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>DP</given-names>
</name>
<etal/>
</person-group>. <article-title>Association between novel oxidative stress markers and C-reactive protein among adults without clinical coronary heart disease</article-title>. <source>Atherosclerosis</source>. <year>2005</year>;<volume>178</volume>(<issue>1</issue>):<fpage>115</fpage>–<lpage>121</lpage>.</citation>
</ref>
<ref id="bibr37-0003319712438956">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Emdin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Passino</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Michelassi</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Prognostic value of serum gamma-glutamyl transferase activity after myocardial infarction</article-title>. <source>Eur Heart J</source>. <year>2001</year>;<volume>22</volume>(<issue>19</issue>):<fpage>1802</fpage>–<lpage>1807</lpage>.</citation>
</ref>
<ref id="bibr38-0003319712438956">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ulmer</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kollerits</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Kelleher</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Diem</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Concin</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Predictive accuracy of the SCORE risk function for cardiovascular disease in clinical practice: a prospective evaluation of 44 649 Austrian men and women</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source>. <year>2005</year>;<volume>12</volume>(<issue>5</issue>):<fpage>433</fpage>–<lpage>441</lpage>.</citation>
</ref>
<ref id="bibr39-0003319712438956">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paolicchi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Emdin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Passino</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Beta-lipoprotein and LDL-associated serum gamma-glutamyltransferase in patients with coronary atherosclerosis</article-title>. <source>Atherosclerosis</source>. <year>2006</year>;<volume>186</volume>(<issue>1</issue>):<fpage>80</fpage>–<lpage>85</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>